Norris Michael H, Rahman Khan Md Siddiqur, Schweizer Herbert P, Tuanyok Apichai
Department of Infectious Diseases and Pathology, College of Veterinary Medicine, Univeristy of Florida, Gainesville, FL, USA.
Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
BMC Microbiol. 2017 Jun 7;17(1):132. doi: 10.1186/s12866-017-1040-4.
The work was undertaken to expand the tools available for researching Burkholderia pseudomallei (Bp), the etiological agent of the tropical disease melioidosis. Melioidosis has the potential to pose a severe threat to public health and safety. In the United States, Bp is listed as a Tier-1 select agent by the Centers for Disease Control and Prevention (CDC), thus requiring high levels of regulation and biosafety level 3 (BSL3) facilities for experimental manipulation of live organisms. An avirulent ∆purM derivative of strain 1026b (Bp82) has proven to be a valuable tool for biosafe research as a select-agent excluded strain, but the high level of genetic diversity between Bp strains necessitates an expansion of the biosafe toolset.
The ∆purM mutation was recapitulated in the Bp 576a strain, a serotype B background. An important difference between strains 1026b and 576a is the lipopolysaccharide (LPS), a major virulence factor and protective antigen. Polyclonal sera from 1026b-challenged non-human primates showed no cross reactivity with strain 576a LPS and low reactivity with whole cell lysate. Strain 576a replicates to higher levels in mouse organs and induces more TNF-α in the lungs of BALB/c mice compared to 1026b. The newly created Bp 576a ∆purM strain, designated 576mn, was auxotrophic for adenine in minimal media, capable of wild-type growth in rich media with addition of adenine, and auxotrophy was abrogated with single-copy complementation. Bp 576mn was unable to replicate in human cells and was avirulent in BALB/c mice following high-dose intranasal inoculation, similar to Bp82. Organ loads indicated a significant reduction in bacterial replication.
In this work, the new biosafe strain 576mn with atypical type B LPS was generated. This strain should prove a valuable addition to the toolkit for biosafe studies of Bp and development of therapeutic and preventative strategies aimed at combatting melioidosis. Strain 576mn is an ideal candidate for select-agent exclusion.
开展这项工作是为了扩充可用于研究类鼻疽杆菌(Bp)的工具,类鼻疽杆菌是热带疾病类鼻疽的病原体。类鼻疽有对公众健康和安全构成严重威胁的可能性。在美国,类鼻疽杆菌被疾病控制与预防中心(CDC)列为一级选择生物制剂,因此对其进行活生物体实验操作需要高水平的监管和生物安全3级(BSL3)设施。菌株1026b的无毒∆purM衍生物(Bp82)已被证明是一种用于生物安全研究的有价值工具,作为一种被排除在选择生物制剂之外的菌株,但类鼻疽杆菌菌株之间的高度遗传多样性使得有必要扩充生物安全工具集。
在血清型B背景的Bp 576a菌株中重现了∆purM突变。1026b和576a菌株之间的一个重要差异是脂多糖(LPS),它是一种主要的毒力因子和保护性抗原。来自受1026b攻击的非人灵长类动物的多克隆血清与576a菌株的LPS无交叉反应,与全细胞裂解物的反应性较低。与1026b相比,576a菌株在小鼠器官中的复制水平更高,并且在BALB/c小鼠的肺部诱导产生更多的肿瘤坏死因子-α(TNF-α)。新创建的Bp 576a ∆purM菌株,命名为576mn,在基本培养基中对腺嘌呤营养缺陷,在添加腺嘌呤的丰富培养基中能够进行野生型生长,并且单拷贝互补可消除营养缺陷。Bp 576mn无法在人细胞中复制,在高剂量鼻内接种后对BALB/c小鼠无毒,类似于Bp82。器官载量表明细菌复制显著减少。
在这项工作中,产生了具有非典型B型LPS的新型生物安全菌株576mn。该菌株应被证明是用于类鼻疽杆菌生物安全研究以及开发旨在对抗类鼻疽的治疗和预防策略的工具集中的一个有价值补充。576mn菌株是被排除在选择生物制剂之外的理想候选菌株。